NASDAQ:PALI

Palisade Bio (PALI) Stock Forecast, Price & News

$0.72

-1.22 (-62.77%)

(As of 08/9/2023 ET)

Compare

Today's Range: $0.60
▼
$0.74
50-Day Range: $1.32
▼
$2.31
52-Week Range: $0.60
▼
$19.99

Volume: 4.29 million shs
Average Volume: 1.04 million shs
Market Capitalization: $4.85 million

P/E Ratio: 0.14
Dividend Yield: N/A
Price Target: $16.00

Palisade Bio MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 2,110.9% Upside
$16.00 Price Target
Short Interest: Healthy
3.23% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.29
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.57) to ($0.90) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

3.0

Analyst's Opinion

Consensus Rating
Palisade Bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.00, Palisade Bio has a forecasted upside of 2,110.9% from its current price of $0.72.
Amount of Analyst Coverage
Palisade Bio has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.23% of the float of Palisade Bio has been sold short.
Short Interest Ratio / Days to Cover
Palisade Bio has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Palisade Bio has recently increased by 342.20%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Palisade Bio does not currently pay a dividend.
Dividend Growth
Palisade Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PALI.

2.1

News and Social Media Coverage

News Sentiment
Palisade Bio has a news sentiment score of -0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Palisade Bio this week, compared to 1 article on an average week.
Search Interest
6 people have searched for PALI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
3 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Palisade Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.25% of the stock of Palisade Bio is held by insiders.
Percentage Held by Institutions
Only 0.13% of the stock of Palisade Bio is held by institutions.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Palisade Bio are expected to grow in the coming year, from ($1.57) to ($0.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Palisade Bio is 0.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.33.
Price to Earnings Ratio vs. Sector
The P/E ratio of Palisade Bio is 0.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 132.33.
Price to Book Value per Share Ratio
Palisade Bio has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Palisade Bio (NASDAQ:PALI) Stock

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.

PALI Price History

30 days | 90 days | 365 days | Advanced Chart

PALI Stock News Headlines

August 9, 2023 | finanznachrichten.de

Palisade Bio, Inc.: Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

August 9, 2023 | marketwatch.com

Palisade Bio Shares Sink After Trial Misses Primary Endpoint

August 10, 2023 | Legacy Research (Ad)

Bizarre Amazon Secret — Not Available on CNN, Fox, or MSNBC

Amazon. It’s one of the most profitable companies on Earth. Yet, according to Brad Thomas, a multi-millionaire, best-selling author, and former economic advisor to President Trump... What few people realize is, thanks to a little-known IRS loophole — billions of dollars get paid out each year...

August 9, 2023 | msn.com

Why Is Palisade Bio Stock Sinking Today?

August 9, 2023 | marketwatch.com

Palisade Bio's Post-Surgery Treatment Trial Misses Primary Endpoint

August 7, 2023 | finance.yahoo.com

PALI - Palisade Bio, Inc.

July 5, 2023 | finance.yahoo.com

Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study

June 22, 2023 | finance.yahoo.com

PALISADES ANNOUNCES NEW FOUND MAKES NEW HIGH-GRADE, AT SURFACE DISCOVERY AT JACKPOT ZONE AT QUEENSWAY PROJECT

August 10, 2023 | Chaikin Analytics (Ad)

Forget NVDA. Buy this A.I. stock instead

Dozens of 100% - 1,000% opportunities over the last decade have led to this one under-the-radar A.I. stock... MORE HERE...

June 14, 2023 | finance.yahoo.com

Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

June 1, 2023 | finanznachrichten.de

Palisade Bio, Inc.: Palisade Bio Promotes J.D. Finley to Chief Executive Officer

June 1, 2023 | msn.com

Palisade Bio appoints J.D. Finley as permanent CEO

June 1, 2023 | finance.yahoo.com

Palisade Bio Promotes J.D. Finley to Chief Executive Officer

May 24, 2023 | finance.yahoo.com

Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts

May 23, 2023 | msn.com

Palisade Bio, Inc. (PALI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

May 18, 2023 | benzinga.com

Ladenburg Thalmann Maintains Buy on Palisade Bio, Lowers Price Target to $16

May 17, 2023 | finance.yahoo.com

PALISADES ANNOUNCES NEW FOUND GOLD INTERCEPTS AT KEATS WEST

May 17, 2023 | msn.com

Ladenburg Thalmann Maintains Palisade Bio (PALI) Buy Recommendation

May 13, 2023 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on Palisade Bio (PALI)

May 12, 2023 | finanznachrichten.de

Palisade Bio, Inc.: Palisade Bio Reports First Quarter 2023 Financial Results

May 12, 2023 | finance.yahoo.com

Palisade Bio Reports First Quarter 2023 Financial Results

May 11, 2023 | finance.yahoo.com

Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

April 22, 2023 | marketwatch.com

S-1: PALISADE BIO, INC.

April 17, 2023 | finance.yahoo.com

Palisade Bio, Inc. (PALI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

April 12, 2023 | benzinga.com

Premarket Mover: Palisade Bio Inc (PALI) Up 0.96%

April 6, 2023 | msn.com

Palisade (PALI) Enrolls First Patient in LB1148 Study in China

April 6, 2023 | finance.yahoo.com

Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148

See More Headlines

Receive PALI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter.

PALI Company Calendar

Last Earnings: 5/12/2023
Today: 8/09/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PALI
CUSIP: N/A
CIK: 1357459
Web: www.palisadebio.com
Phone: (858) 704-4900
Fax: N/A
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $16.00
High Stock Price Forecast: $16.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +2,110.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 0.14
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,260,000.00
Net Margins: N/A
Pretax Margin: -4,958.00%
Return on Equity: -115.68%
Return on Assets: -89.99%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.88
Quick Ratio: 10.88

Sales & Book Value

Annual Sales: $10,000.00
Price / Sales: 484.88
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.24 per share
Price / Book: 0.17

Miscellaneous

Outstanding Shares: 6,700,000
Free Float: 6,613,000
Market Cap: $4.85 million
Optionable: Not Optionable
Beta: 1.67

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. J. D. Finley (Age 65)
CEO & Director
Comp: $573.6k

Dr. Herbert B. Slade FAAAAI
M.D., Chief Medical Officer

Mr. Ryker Willie
Sr. VP of Fin. & Corp. Controller

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

PALI Stock - Frequently Asked Questions

Should I buy or sell Palisade Bio stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Palisade Bio in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PALI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PALI, but not buy additional shares or sell existing shares.
View PALI analyst ratings or view top-rated stocks.
What is Palisade Bio's stock price forecast for 2023?: 1 equities research analysts have issued 1 year price objectives for Palisade Bio's stock. Their PALI share price forecasts range from $16.00 to $16.00. On average, they predict the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 2,110.9% from the stock's current price.
View analysts price targets for PALI or view top-rated stocks among Wall Street analysts.
How have PALI shares performed in 2023?: Palisade Bio's stock was trading at $5.20 at the beginning of 2023. Since then, PALI shares have decreased by 86.1% and is now trading at $0.7237.
View the best growth stocks for 2023 here.
Are investors shorting Palisade Bio?: Palisade Bio saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 212,700 shares, an increase of 342.2% from the June 30th total of 48,100 shares. Based on an average daily volume of 342,800 shares, the days-to-cover ratio is currently 0.6 days. Approximately 3.2% of the shares of the company are short sold.
View Palisade Bio's Short Interest.
When is Palisade Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our PALI earnings forecast.

How were Palisade Bio's earnings last quarter?: Palisade Bio, Inc. (NASDAQ:PALI) issued its quarterly earnings results on Friday, May, 12th. The company reported ($0.54) earnings per share for the quarter. The firm had revenue of $0.25 million for the quarter.
What is Palisade Bio's stock symbol?: Palisade Bio trades on the NASDAQ under the ticker symbol "PALI."
How do I buy shares of Palisade Bio?: Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Palisade Bio's stock price today?: One share of PALI stock can currently be purchased for approximately $0.72.
How much money does Palisade Bio make?: Palisade Bio (NASDAQ:PALI) has a market capitalization of $4.85 million and generates $10,000.00 in revenue each year.
How can I contact Palisade Bio?: Palisade Bio's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The official website for the company is www.palisadebio.com. The company can be reached via phone at (858) 704-4900 or via email at investor@senecabio.com.

This page (NASDAQ:PALI) was last updated on 8/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial